Stay updated with breaking news from Christopher Posner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cara Therapeutics Inc., a Stamford-headquartered commercial-stage biopharmaceutical company focused on creating a new treatment paradigm to improve the lives of patients suffering from pruritus, has entered into a royalty interest purchase and sale agreement with HealthCare Royalty (HCRx), also based in Stamford.
Cara Therapeutics, Inc. (NASDAQ:CARA) Q2 2023 Earnings Call Transcript August 7, 2023 Cara Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.00058 EPS, expectations were $0.56. Operator: Thank you for standing by, and welcome to Cara Therapeutics’ Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. [Operator Instructions]. […]
Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) CEO Christopher Posner sold 4,307 shares of the stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $3.07, for a total value of $13,222.49. Following the completion of the sale, the chief executive officer now directly owns 168,207 shares […]
Cara Therapeutics and VFMCRP have announced that the US’s NICE has recommended Kapruvia (difelikefalin) to treat CKD-associated pruritus.
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus